Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.


LuPSMA: The Specifics (Part 2)

A whole new form of treatment for metastatic castrate-resistant prostate cancer (mCRPC) is here:  PSMA-targeting therapy.  The first PSMA-targeting therapy approved in the U.S. – with more being tested now in clinical trials – is LuPSMA (177Lu-PSMA-617; Pluvicto®), previously discussed here. We asked medical oncologist and PCF-funded scientist Michael J.. Read More


LuPSMA: A Whole New Class of Treatment for Prostate Cancer (Part 1)

PSMA is a molecule that sits on the surface of prostate cancer cells, and we can look right at it.  It can’t hide from us – even in bits of cancer no bigger than a grain of rice – because, thanks to research funded by PCF, newly-approved radioactive tracers that. Read More


Researchers Identify a New Subtype of Advanced Prostate Cancer

A PCF-funded study published in the prestigious journal Science has identified a new subtype of castration-resistant prostate cancer (CRPC). Understanding how genes and proteins “drive” this particular type of cancer may lead to new treatments. In the early stages, prostate cancer cells are driven by androgens (e.g., testosterone), which naturally. Read More


A Powerful Advocate

It’s good to have friends in high places, and men with prostate cancer have a knowledgeable and powerful advocate working for them:  Karen Knudsen, Ph.D., M.B.A., a PCF-funded investigator who in 2021 became the first woman, and the first basic science researcher, to be named CEO of the American Cancer. Read More


Metastatic Prostate Cancer: Don’t Accept Complacency!

“This is all we can do” is a phrase no cancer patient wants to hear, especially someone with metastatic disease.  Medical oncologist and PCF-funded investigator Andrew Armstrong, M.D., M.Sc., hears those six words a lot – from patients who have come to see him at Duke University’s Cancer Center, a. Read More


Why Genes Matter

We're in the midst of a revolution in how prostate cancer is treated — and it's being led by new knowledge about the genes behind the disease. Read More